Status:
ACTIVE_NOT_RECRUITING
Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery
Lead Sponsor:
IRCCS San Raffaele
Conditions:
Brain Metastases, Adult
Eligibility:
All Genders
18+ years
Brief Summary
Brain metastases (BM) represents a devastating clinical reality, carrying an estimated survival time of less than one year. Number of reasons, including complicated tumor biology and difficulties in m...
Detailed Description
Experimental procedure: Serum levels of glutamic oxaloacetic transaminase (GOT1), glutamate Pyruvate Transaminase (GPT) and lactate dehydrogenase (LDH) levels and serum glutamate, aspartate and lacta...
Eligibility Criteria
Inclusion
- Inclusion Criteria (Target group)
- Adult patients carrying melanoma, breast or lung cancer BM of new diagnosis
- Patients eligible to SRS-GK treatment
- Inclusion Criteria (Control group 1)
- \- Adult patients carrying melanoma, breast or lung cancer without BM
- Inclusion Criteria (Control group 2)
- Adult patients carrying intracranial extra-axial benign tumor
- Patients eligible to SRS-GK treatment
- Exclusion Criteria:
- Acute or chronic liver disease
- Severe anemia (Hb \<8g/dl)
- Pregnant or breastfeeding patient
- Pediatric patients
- Patients not able to express informed consent
Exclusion
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04785521
Start Date
July 1 2020
End Date
December 31 2025
Last Update
June 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS San Raffaele Scientific Institute
Milan, Milan, Italy, 20132